Sanofi has experienced a series of internal setbacks on the R&D front in recent months, but its close partnership with Regeneron is still paying off with promising late-stage data.
Avalon Ventures is kick-starting the first biotech enterprise in its half-billion dollar portfolio deal with GlaxoSmithKline, launching a startup named Sitari Pharmaceuticals which will pursue research work out of Stanford University with an eye to developing a new drug for celiac disease.
Array BioPharma Chief Scientific Officer Kevin Koch is leaving the biotech after 15 years, news that sent the company's shares down more than 5% on Thursday morning.
Canada's Oncolytics Biotech trumpeted some promising late-stage results for its viral head and neck cancer therapy, but a distortion in the company's overall survival data rattled investors, sending its shares down as much as 8.6% on Thursday.
Combination cancer therapies are all the rage these days in the oncology field. Now two of the giant players in the cancer R&D arena have decided to match their top prospects to see if they can make a bigger impact on melanoma.
After two years of building up its knowledge of the human microbiome, tiny Seres Health has emerged from stealth mode today with $10.5 million in venture cash from Flagship Ventures and a business plan to develop new therapies dubbed "Ecobiotics."
The FDA set up a potentially serious roadblock for Forest Laboratories and its partner Gedeon Richter, rejecting their application for the schizophrenia/bipolar drug cariprazine and likely delaying any possible approval until the agency gets additional clinical trial data.
Slightly less than a year after GlaxoSmithKline and Amicus Therapeutics reported that the first step in their Phase III program for the Fabry disease drug Amigal--or migalastat HCI--had ended in failure, the pharma giant has bowed out of its development collaboration.
Daiichi Sankyo's atrial fibrillation-treating edoxaban posted promising results in Phase III, matching the stroke-prevention prowess of warfarin with a better safety profile, but the drug may struggle to carve out market share in a cluttered space.
Argos Therapeutics is working to get out from under the shadow of Dendreon and its disappointing Provenge, and now the North Carolina company has the cash it needs to get its kidney cancer candidate through Phase III and prove the promise of its dendritic cell platform.
Moderna Therapeutics is having quite a year, and the Cambridge, MA, biotech just put a $110 million capstone on 2013, raising a colossal new round and riding high on technology that promises to transform the human body into a drug factory.
After reportedly striking out in an effort to find a buyer, Clovis Oncology has struck up a deal of its own, agreeing to buy Italy's Ethical Oncology Science and its mid-stage targeted cancer drug lucitanib for up to $420 million.
I'm Rebecca Friend, the new publisher of FierceMarkets' Life Sciences group. I've been with the Life Sciences group for the past two years focusing primarily in the pharma industry, and now I am looking forward to expanding my role across the entire Life Sciences network of publications.
The Bay Area's BioMarin Pharmaceutical had an easy time at the FDA, winning the support of an agency panel for its latest rare-disease treatment and feeding expectations for a near-term approval.
Google made major waves two months ago when it landed former Genentech CEO Art Levinson to run its still-murky Calico offshoot. Now the biotech elder statesman is reuniting with his former chief medical officer, convincing Hal Barron to leave his post at Roche and oversee R&D at the nascent company.
Last year, Anthera Pharmaceuticals pulled the plug on its lead drug after the cardiovascular disease treatment ran into some insurmountable efficacy problems in Phase III but failed to mention that the now-discarded varespladib actually increased patients' risks of heart attack and stroke. The study's lead investigator said Anthera dragged its feet in releasing the data.
The FDA has accepted an NDA for Nektar Therapeutics' naloxegol, triggering a $70 million milestone payment from partner AstraZeneca.
AstraZeneca and its stilted R&D division aren't scheduled to move to Cambridge, U.K., until 2016, but the drugmaker can't wait to settle in at what it calls "one of the world's preeminent biosciences hotspots," planning to send an advance team of scientists to plant some collaborative seeds.
Gilead Sciences is sprinting toward FDA approval with the promising idelalisib, a targeted cancer therapy that met all its Phase III endpoints, giving the company another boost in the competitive landscape for chronic lymphocytic leukemia treatments.
In the latest trove of promising Phase III data for Amgen's T-Vec, the cancer-fighting virus increased overall survival by four months compared to standard growth factor therapy, driving optimism that the drug can win approval and make some noise in the melanoma market.